HeimEVGN • NASDAQ
add
Evogene Ltd
Við síðustu lokun
2,96 $
Dagbil
2,80 $ - 2,87 $
Árabil
2,29 $ - 10,40 $
Markaðsvirði
14,17 m. USD
Meðalmagn
27,91 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
BioSpace
fyrir 14 mínútum
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1,87%
www.tradingview.com
fyrir 12 mínútum
Tired of Being Beaten Up by the Equity Markets? Try This Strategy
0,96%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 914,00 þ. | 39,76% |
Rekstrarkostnaður | 7,00 m. | -13,54% |
Nettótekjur | -5,42 m. | 22,84% |
Hagnaðarhlutfall | -592,89 | 44,79% |
Hagnaður á hvern hlut | -1,06 | 37,65% |
EBITDA | -6,01 m. | 17,18% |
Virkt skatthlutfall | -0,02% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 20,91 m. | -38,28% |
Heildareignir | 40,97 m. | -23,19% |
Heildarskuldir | 21,03 m. | -5,41% |
Eigið fé alls | 19,94 m. | — |
Útistandandi hlutabréf | 5,10 m. | — |
Eiginfjárgengi | 4,93 | — |
Arðsemi eigna | -37,73% | — |
Ávöxtun eigin fjár | -70,24% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -5,42 m. | 22,84% |
Handbært fé frá rekstri | -5,46 m. | -7,15% |
Reiðufé frá fjárfestingum | 3,21 m. | 140,63% |
Reiðufé frá fjármögnun | -151,00 þ. | -101,45% |
Breyting á handbæru fé | -2,43 m. | 12,14% |
Frjálst peningaflæði | 5,43 m. | 377,69% |
Um
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
Framkvæmdastjóri
Stofnsett
2002
Vefsvæði
Starfsfólk
142
